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its features in culture were atypical (3). In 2015, Sigler 
determined that this isolate belonged to a new Emmon-
sia-like species, which she described as E. helica (3). 
Another fatal case of Emmonsia infection was reported 
from California in a patient after an orthotopic liver 
transplant (4). An isolate from that patient also was con-
firmed as E. helica (I. Schwartz et al., unpub. data).
Although the travel history for the second case-patient 
was not reported (4) and the patient in this report had re-
sided in Mexico, these cases suggest that the area of en-
demicity of E. helica may include California. This finding 
is further supported by 2 other fatal cases of atypical my-
coses reported in HIV-infected men from California (5); 
histopathologic findings of hyphae and multiple budding 
yeasts were consistent with E. helica (I. Schwartz et al., 
unpub. data). Investigations are under way to characterize 
the geographic and host range of E. helica and to clarify 
the phylogenetic relationships among members of the fam-
ily Ajellomycetaceae comprising the genera Emmonsia, 
Blastomyces, Histoplasma and others because recent stud-
ies have uncovered far greater complexity than previously 
supposed (1,6).
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During January–April 2015, a major outbreak of conjunctivi-
tis on Réunion Island caused a large public health impact. 
On the basis of general practitioner consultations, emergen-
cy department visits, and eye medication sales during the 
13-week epidemic, we estimated a total healthcare cost of 
€3,341,191 from the outbreak.
During January–April 2015, a major outbreak of acute hemorrhagic conjunctivitis occurred on Réunion Is-
land, causing a heavy impact on the national healthcare 
system of France (1). Réunion Island, a French overseas 
administrated territory, is located in the Indian Ocean be-
tween Madagascar and Mauritius; it has a surface area of 
2,512 km2 and a population of ≈840,000 (1.3% of France’s 
population, including the nation’s overseas territories; 
https://www.insee.fr/fr/statistiques/2119468). 
The island is included in the national health insurance 
(NHI) program of France. Réunion Island’s health system 
is similar to that of France; however, most patients on the 
island do not pay provider health fees directly. NHI pays 
the general practitioner (GP), the pharmacist, or hospi-
tal. Rarely, the patients pay for the GP consultations and 
emergency department (ED) visits, but these costs will be 
refunded to the patients by the NHI. Healthcare costs are 
higher (≈30%) on the island than in mainland France. In 
2015, total healthcare expenditures in Réunion Island were 
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€2.561 billion; which is 1.6% of France’s healthcare spend-
ing (≈€163 billion) for that year.
A syndromic surveillance system, the Organisation de 
la surveillance coordonnée des urgences (Organization of 
coordinated emergency surveillance [OSCOUR]) network, 
is based on data collected by all EDs across the country, in-
cluding in French overseas territories (2). Data are collected 
daily directly from patients’ computerized medical files that 
are completed during medical consultations. For each ED 
visit, patient age, sex, city of residence, and the diagnosis are 
recorded. This enables analysis by syndromic groups, age 
groups, and geographic areas. The diagnosis is categorized 
according to the International Classification of Diseases, 
10th edition (ICD-10; http://www.icd10data.com/). Public 
health indicators are routinely monitored by using temporal 
and spatiotemporal analyses, including the number of ED 
visits for conjunctivitis (ICD-10 code B30 and subcodes, 
code H10 and subcodes, and code H11 and subcodes).
At the end of January 2015, by using spatiotemporal 
analysis of data from the OSCOUR network, we detected 
a cluster of conjunctivitis cases in the western part of the 
island that occurred during January 26–February 1 (week 5 
of 2015). We organized conjunctivitis surveillance within 
the framework of an existing sentinel project involving 56 
volunteer GPs located throughout the island who reported 
weekly to the Indian Ocean regional institute for public 
health surveillance agency, known as Cire OI (3).
The outbreak on Réunion Island began during week 
5 then quickly spread throughout the island and ended in 
week 17 (end of April) of 2015. Data from ED visits show 
that all age groups were affected. By using the GP sentinel 
network and NHI data (1), we estimated the total number 
of GP consultations for conjunctivitis on the island to be 
100,094. During this outbreak, we sent regular epidemio-
logic updates to health professionals to inform them of the 
ongoing epidemiologic situation and available preventive 
measures. Health authorities also published a press release 
for the general public.
On the basis of these data and the major impact for 
public health, we estimated the cost of this outbreak. We 
compiled the cost of different indicators: GP consultations, 
ED visits, and eye medication sales. On Réunion Island, a 
GP consultation fee of €27.60 and an ED visit fee of €52.60 
are reimbursed by NHI. For medicated eye drop sales, we 
extracted data (number of sales by week and cost) from 
France’s NHI information system, SNIIR-AM (4). During 
the outbreak period, 187,126 medicated eye drop kits were 
purchased and reimbursed, at a total cost of €566,443. For 
activity related to conjunctivitis, the cost for GP consulta-
tions was €2,762,597 and for ED visits was €12,151 (Table). 
During weeks 5–17, the healthcare cost was estimated at 
€3,341,191. The total cost is underestimated, however, be-
cause it did not include costs to individuals and businesses, 
including sick leave, work absenteeism of parents for sick 
children, and some persons who had conjunctivitis but did 
not consult a physician. 
These data demonstrate that acute outbreaks of ill-
ness caused by nonfatal agents can have substantive public 
health and economic impact. In France, where medical costs 
are reimbursed by the state, an outbreak of this magnitude, 
even if virulence is negligible, should be examined thor-
oughly. Information for the public and health professionals 
should be strengthened by recurring prevention campaigns 
with a focus on hygiene, such as washing hands frequently; 
avoiding rubbing the eyes; covering one’s mouth and nose 
when coughing or sneezing; and avoiding sharing linen, 
towels, or any objects owned by affected persons.
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Table. Weekly volume and total costs of medicated eye drop sales, consultations with GPs, and ED visits for conjunctivitis outbreak, 





No. GP consultations 
for conjunctivitis 
No. ED visits for 
conjunctivitis 
Total cost of eye 
drop sales, € 
Total cost of GP 
consultations, € 
Total cost of ED 
visits, € 
5 7,126 2,641 19 21,206 72,887 999 
6 6,818 1,937 9 20,198 53,453 473 
7 10,379 3,537 17 31,199 97,617 894 
8 14,079 7,439 17 42,646 205,326 894 
9 25,831 13,845 33 78,083 382,108 1,736 
10 27,345 20,895 41 82,198 576,711 2,157 
11 31,866 20,648 21 101,453 569,892 1,105 
12 15,339 9,141 15 46,990 252,279 789 
13 14,726 6,954 17 43,034 191,921 894 
14 11,049 4,832 13 32,717 133,371 684 
15 8,180 3,369 17 24,166 92,977 894 
16 8,109 2,593 9 24,040 71,574 473 
17 6,279 2,264 3 18,514 62,479 158 
Total by category 187,126 100,094 231 566,443 2,762,597 12,151 
Total costs    3,341,191 
*ED, emergency department; GP, general practitioners. 
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We report 1,327 probable cases of dengue in Burkina Faso 
in 2016. Of 35 serum samples tested by a trioplex test, 19 
were confirmed dengue virus (DENV)‒positive: 11 DENV-
2, 6 DENV-3, 2 nontypeable, and 1 DENV-2/DENV-3 co-
infection. Molecular testing should be conducted to cor-
rectly identify causative agents in this complex infectious 
disease landscape.
Dengue is an emerging viral disease mainly found in the tropical and subtropical zones, and a major public 
health concern worldwide (1–3). Dengue fever is a mosqui-
toborne viral infection caused by 4 distinct dengue viruses 
(DENVs): DENV-1‒4. In some countries of sub-Saharan 
Africa, the circulation of all 4 viruses has been reported (4). 
However, availability of rapid tests and molecular diagno-
sis by reverse transcription PCR (RT-PCR) in resource-
limited settings remains a challenge.
During October 29, 2016‒November 21, 2016, we 
screened 1,947 suspected dengue cases using a rapid diag-
nostic test (SD BIOLINE Dengue Duo, Standard Diagnos-
tics, Seoul, South Korea), which detects DENV nonstruc-
tural protein 1 (NS1) and dengue-specific antibodies (IgM 
and IgG), in response to an outbreak of acute febrile illness 
in Burkina Faso. All patients with acute febrile illness during 
this period were suspected to have dengue; notably, some 
patients had biphasic fever with severe headache, myalgia, 
arthralgia, and rash. Patients who tested positive for NS1 
or DENV antibodies were considered to have a probable 
DENV infection. All participants provided informed consent 
as specified by the Declaration of Helsinki, and approval of 
this study was obtained from the national ethics committee.
Of the 1,947 blood samples tested, 1,327 were positive 
for NS1, DENV antibodies, or both. Of the 13 country re-
gions investigated, the central region, which includes the city 
of Ouagadougou, was the most affected, having 1,679 of the 
1,947 suspected cases (case fatality ratio 1.2% [20/1,679]) 
and 1,307 of the 1,327 probable cases. Of the 20 deceased 
patients, 18 were positive for NS1 and 2 were positive for 
NS1 and DENV IgM. The outbreak peaked November 
11‒14. Blood samples from 35 randomly selected patients 
were sent to the National Reference Laboratory for Influenza 
(Bobo-Dioulasso, Burkina Faso) for confirmation using the 
Centers for Disease Control and Prevention trioplex real-
time RT-PCR protocol (5) followed by singleplex to iden-
tify the infecting DENV serotype. Of the 35 patient samples 
that were selected, 22 were positive for NS1, 3 were posi-
tive for both NS1 and IgG, 3 were positive for IgG, 2 were 
